MedTrace Logo

Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients

NCT03816306 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-01-18

No results posted yet for this study

Summary

To evaluate the clinical and echocardiographic outcome of LCZ696 therapy in HFrEF (NYHA Class II - IV and EF =≤ 40%).patients, in addition to the efficacy of LCZ696 in reducing mortality and rehospitalisation rate.

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

LCZ 696

LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.

Sponsors & Collaborators

  • Mohammed Alnims

    lead OTHER

Principal Investigators

  • Magdy Abdelhamid, MD, FACC, FESC, FSCAI · Professor of Cardiovascular Medicine, Cairo University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-12-01
Completion
2019-12-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03816306 on ClinicalTrials.gov